Flu Vaccine for Breast Cancer

Overseen By Angela Limburg, RN, BSN

Age: 18+

Sex: Any

Trial Phase: Phase 1

Sponsor: Rush University Medical Center

Must not be taking: Anticoagulants, Corticosteroids, Immunosuppressants

Disqualifiers: Uncontrolled illness, Egg allergy, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Approved in 2 Jurisdictions This treatment is already approved in other countries

Compensation: Varies

Number of Visits: Unknown

Duration: 3 months

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests whether administering the flu vaccine (Fluzone Quadrivalent) directly into breast cancer tissue can enhance the body's ability to combat the cancer. Researchers aim to determine the safety and efficacy of this method for triple-negative and HER2+ breast cancer types. Women diagnosed with one of these types and planning to start chemotherapy soon might be suitable candidates. The study involves gradually increasing vaccine doses to observe reactions in the body and tumor. Participants will provide blood, stool, and tumor samples for testing throughout the study. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants a chance to be among the first to receive this novel approach.

Will I have to stop taking my current medications?

The trial excludes patients who are currently on anticoagulant therapy, corticosteroids, or immunosuppressive agents, so you would need to stop these medications to participate.

Is there any evidence suggesting that this treatment is likely to be safe for humans?

Research shows that Fluzone Quadrivalent, the vaccine tested in this trial, is generally well-tolerated. Studies have found it effective in preventing the flu, even in individuals with other health issues. The vaccine is already approved for flu prevention, indicating its well-established safety.

In earlier studies, some participants experienced mild side effects, such as soreness at the injection site, tiredness, or a mild fever. These reactions are common for many vaccines, while serious side effects remain rare.

As this trial is in its early stages, the main focus is on safety. Researchers are closely monitoring participants' responses to the vaccine. Overall, existing evidence suggests the vaccine is safe, but more information will be gathered during this study. ^{1 2 3 4 5}

Why do researchers think this study treatment might be promising?

Unlike the standard treatments for breast cancer, which typically involve surgery, chemotherapy, and radiation, the Fluzone Quadrivalent vaccine is administered directly into the tumor. This approach is unique because it uses an intratumoral delivery method to potentially stimulate the immune system right at the tumor site. Researchers are excited about this treatment because it could trigger a powerful immune response against cancer cells, harnessing the body's natural defenses in a new way. This method might offer a more targeted treatment option with fewer systemic side effects compared to traditional therapies.

What evidence suggests that this treatment might be an effective treatment for breast cancer?

Research has shown that the Fluzone Quadrivalent vaccine typically protects against the flu by aiding the immune system in combating the flu virus. In this trial, participants will receive the Fluzone Quadrivalent vaccine injected directly into the tumor to test its potential to help the body fight breast cancer by triggering the immune system to attack the cancer. Although limited data exists on its use for cancer, this approach relies on a strong understanding of how the vaccine enhances immune defenses. ^{1 2 6 7 8}

Who Is on the Research Team?

Ruta Rao

Principal Investigator

Rush University Medical Center

Are You a Good Fit for This Trial?

This trial is for women with triple-negative or HER2+ breast cancer who are about to start standard chemotherapy. They should be relatively active and able (ECOG 0-2) and have a confirmed diagnosis through tissue samples. The study excludes certain individuals, but the criteria aren't fully listed here.

Inclusion Criteria

My breast cancer is confirmed as either triple-negative or HER2 positive.

I am able to care for myself and perform daily activities.

I am set to receive recommended initial chemotherapy.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive 2 doses of seasonal flu vaccine directly into breast cancer tissue, with increasing doses across groups

3 months

Multiple visits for vaccine administration and sample collection

Follow-up

Participants are monitored for safety and effectiveness after treatment, including assessment of dose-limiting toxicity

3 months post surgery

What Are the Treatments Tested in This Trial?

Interventions

• Fluzone Quadrivalent

Trial Overview The study tests injecting flu vaccine directly into breast cancer tumors before chemo starts. Participants will receive different doses of the vaccine in palpable or non-palpable tumors, administered by trained professionals using touch or ultrasound guidance.

How Is the Trial Designed?

Group I: Intratumoral influenza vaccine Experimental Treatment 1 Intervention

Fluzone Quadrivalent is already approved in United States, European Union for the following indications:

Approved in United States as Fluzone Quadrivalent for:

• Prevention of disease caused by influenza A subtype viruses and type B virus contained in the vaccine

Approved in European Union as Fluzone Quadrivalent for:

• Prevention of disease caused by influenza A subtype viruses and type B virus contained in the vaccine

Who Is Running the Clinical Trial?

Rush University Medical Center

Lead Sponsor

Trials

448

Recruited

247,000+

Published Research Related to This Trial

Vaccines for melanoma are considered safe and have lower toxicity compared to current treatments, making them a promising option for patients.

Clinical trials indicate that these vaccines can effectively stimulate immune responses, leading to improved outcomes such as longer recurrence-free survival in patients compared to control groups.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Melanoma vaccines: what we know so far. Bystryn, JC., Reynolds, SR.[2015]

The MFCH401-based tricomponent anti-HER2 cancer vaccine significantly enhances the immune response against HER2-overexpressing breast cancer cells, showing stronger humoral and cellular immunity compared to simpler two-component vaccines.

Incorporating the lipopeptide Pam3CSK4 into the vaccine formulation was found to provide superior immunostimulatory activity, improving the overall effectiveness of the vaccine in targeting breast cancer.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Synthesis and functional studies of self-adjuvanting multicomponent anti-HER2 cancer vaccines. Feng, Q., Yu, X., Wang, Y., et al.[2022]

Current breast cancer vaccines typically target only one part of the immune system, which may limit their effectiveness; a more comprehensive approach is needed.

Recent advances in developing a multivalent glycolipopeptide vaccine have shown promising results in stimulating multiple immune responses, potentially improving both treatment and prevention of breast cancer.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Recent advances in multivalent self adjuvanting glycolipopeptide vaccine strategies against breast cancer. Chentoufi, AA., Nesburn, AB., BenMohamed, L.[2021]

In a phase II study involving 187 patients with advanced cancers, the oral administration of SF-SP showed promising efficacy, with one complete response in breast cancer and 29 partial responses across various cancer types, particularly colorectal, gastric, and breast cancers.

The treatment was well-tolerated, with no serious toxicity reported, indicating a favorable safety profile for SF-SP in this patient population.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[Cooperative phase II study of spansule tegafur (SF-SP)]. Taguchi, T.[2013]

ICRF-187, administered at a dose of 3 g/M2/day for 3 days, was well tolerated in a phase II trial involving 56 children with solid tumors and acute leukemia, with the main side effect being hematopoietic depression.

Despite being well tolerated, ICRF-187 showed no objective responses in treating leukemia or solid tumors, suggesting that it may require a different administration schedule to be effective.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Phase II trial of ICRF-187 in children with solid tumors and acute leukemia. Vats, T., Kamen, B., Krischer, JP.[2019]

E75, an immunogenic peptide from the HER2 protein, has been shown to be safe and effective in stimulating an immune response in breast cancer patients when used as a vaccine with an immunoadjuvant.

In a study of 187 patients, those vaccinated with E75 + GM-CSF had a 5-year disease-free survival rate of 89.7%, significantly higher than the 80.2% in the control group, indicating a 48% reduction in the risk of cancer recurrence.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Clinical Development of the E75 Vaccine in Breast Cancer. Clifton, GT., Gall, V., Peoples, GE., et al.[2020]

The MFL regimen (mitoxantrone, high-dose 5-FU, and leucovorin) showed limited efficacy in treating previously treated advanced breast cancer, with only a 7.6% overall objective response rate and a median survival of 16 months among 13 patients.

Significant toxicities were observed, including cardiotoxicity and leukopenia, highlighting the need for careful monitoring, especially in patients with prior chemotherapy or heart issues.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity. Yen, CC., Tung, SL., Hsieh, RK., et al.[2019]

The MLF regimen, which combines mitoxantrone, leucovorin, and continuous infusion of 5-fluorouracil, showed a 46% overall response rate in 27 patients with advanced breast cancer, with a 100% response rate in previously untreated patients.

The treatment demonstrated manageable toxicity, with only 26% of patients experiencing grade 3 nausea/vomiting and 4% experiencing grade 4 hematological toxicity, suggesting it is a viable option for patients, including those who have been heavily pretreated.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Mitoxantrone, leucovorin and high-dose infusional 5-fluorouracil: an effective and well-tolerated regimen for the treatment of advanced breast cancer. Wils, JA.[2019]

The phase I clinical trial involving 10 patients with metastatic breast cancer demonstrated that the Her-2/neu multipeptide vaccine was safe and well-tolerated, with local erythema being the only reported side effect.

The vaccine successfully induced Her-2/neu-specific antibodies in 8 out of 10 patients, suggesting potential for clinical benefit similar to existing anti-Her-2 antibody therapies, while also reducing regulatory T cells that may suppress immune responses.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study. Wiedermann, U., Wiltschke, C., Jasinska, J., et al.[2019]

MF59® adjuvanted trivalent influenza vaccines were effective in preventing laboratory-confirmed influenza in older adults, showing a vaccine effectiveness of 45% compared to no vaccination, particularly effective against influenza A(H1N1) with a 61% effectiveness.

While these adjuvanted vaccines were more effective than no vaccination, they were associated with a higher incidence of local and systemic adverse events compared to traditional non-adjuvanted vaccines.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Systematic review of the efficacy, effectiveness and safety of MF59® adjuvanted seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals ≥18 years of age. O Murchu, E., Comber, L., Jordan, K., et al.[2023]

The study demonstrated that a survivin peptide microparticle vaccine significantly slowed tumor growth in a triple negative breast cancer model using 4T1 tumor cells in mice, indicating its potential efficacy as an immunotherapy.

Vaccination led to a specific immune response, as evidenced by increased gamma interferon production in splenocytes, suggesting that targeting survivin could be a promising approach for treating triple negative breast cancer.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Survivin (BIRC5) Peptide Vaccine in the 4T1 Murine Mammary Tumor Model: A Potential Neoadjuvant T Cell Immunotherapy for Triple Negative Breast Cancer: A Preliminary Study. Burkholz, SR., Herst, CV., Carback, RT., et al.[2023]

In the GIADA trial involving 43 premenopausal patients with Luminal B-like breast cancer, a pathologic complete response (pCR) was achieved in 16.3% of patients, with a notably higher response rate of 50% in those with PAM50 Basal subtype tumors.

The study found that tumor-infiltrating lymphocytes (TILs) and immune-related gene expression were significantly associated with pCR, suggesting that a more immune-activated tumor microenvironment may enhance the effectiveness of immunotherapy in this patient group.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial. Dieci, MV., Guarneri, V., Tosi, A., et al.[2023]

Citations

1. clinicaltrials.gov clinicaltrials.gov/study/NCT06229392

A Study to Evaluate the Intratumoral Influenza Vaccine ... This Phase 1 study will assess the safety and efficacy (usefulness) of administering 2 doses of seasonal flu vaccine directly into breast cancer tissue (primary ...

2. fda.gov fda.gov/vaccines-blood-biologics/vaccines/fluzone-quadrivalent-fluzone-high-dose-quadrivalent-fluzone-intradermal-quadrivalent-fluzone

Fluzone Quadrivalent, Fluzone High-Dose Quadrivalent Fluzone Southern Hemisphere is a vaccine indicated for active immunization for the prevention of disease caused by influenza A subtype viruses and type B virus ...

3. clinicaltrials.gov clinicaltrials.gov/study/NCT02258334

NCT02258334 | Study of Fluzone® Quadrivalent, ... The aim of this trial is to evaluate the safety and immunogenicity of the 2014-2015 formulations of Fluzone® Quadrivalent and Fluzone® Intradermal vaccines ...

4. fda.gov fda.gov/media/132238/download

Package Insert - Fluzone High-Dose Quadrivalent Safety, immunogenicity, and efficacy of Fluzone High-Dose Quadrivalent have been evaluated in adults 65 years of age and older [see Adverse Reactions (6.1) and ...

5. cdc.gov cdc.gov/flu/vaccine-types/flu-zone.html

Fluzone High-Dose Seasonal Influenza Vaccine A randomized efficacy study published in the New England Journal of Medicine indicated that the trivalent high-dose vaccine was 24% more ...

6. clinicaltrials.gov clinicaltrials.gov/study/NCT02563093

NCT02563093 | Study of Fluzone® Quadrivalent, ... The aim of the study is to evaluate the safety and immunogenicity of the 2015-2016 formulations of Fluzone Quadrivalent and Fluzone Intradermal Quadrivalent ...

7. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC6491273/

Influenza vaccines in immunosuppressed adults with cancer Observational data suggest lower mortality and infection‐related outcomes with influenza vaccination. The strength of evidence is limited by the small number of ...

8. ecdc.europa.eu ecdc.europa.eu/sites/default/files/documents/seasonal-influenza-vaccines-systematic-review-efficacy.pdf

seasonal-influenza-vaccines-systematic-review ... - ECDC Fluzone High-Dose Study. Completed. NCT03183908. Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza. Vaccines. Completed.